- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07714200
Abstinence Reinforcement Therapy for Veterans Who Smoke Tobacco and Are Experiencing Homelessness (New HART)
15 de julio de 2026 actualizado por: VA Office of Research and Development
Seventy to eighty percent of Veterans experiencing homelessness (VEH) smoke, which is four times the rate of the U.S. population and 2.5 times higher than among impoverished Americans.
Smoking- related deaths among persons experiencing homelessness occur at double the rate seen among more stably housed people.
The purpose of this study study is to evaluate the effectiveness of an intervention to help Veterans experiencing homelessness stop smoking.
The intervention, called Abstinence Reinforcement Therapy + (ART+), includes telehealth-based counseling, smoking cessation aids, and mobile contingency management (mCM).
mCM is an intervention in which participants are paid for smoking abstinence.
120 Veterans who smoke cigarettes and are experiencing homelessness will be randomly assigned to receive either ART+ or usual smoking cessation care.
The primary outcome to be evaluated is the rate at which Veterans assigned to the ART+ condition report smoking abstinence and have their abstinence verified using salivary testing.
Descripción general del estudio
Estado
Aún no reclutando
Condiciones
Descripción detallada
Significance to VA: Seventy to eighty percent of Veterans experiencing homelessness (VEH) smoke, which is four times the rate of the U.S. population and 2.5 times higher than among impoverished Americans.
Smoking- related deaths among persons experiencing homelessness occur at double the rate seen among more stably housed people.
While there are numerous challenges to smoking cessation among Veterans experiencing homelessness, four in five homeless smokers report interest in quitting.
Innovation and Impact: The investigators recently developed and evaluated the effectiveness of a multi-component intervention called Abstinence Reinforcement Therapy (ART), which combined five sessions of telehealth-based cognitive-behavioral therapy, provision of smoking cessation aids, and four weeks of mobile contingency management (mCM).
The investigators have added an additional CM period of eight weeks and opportunities for booster calls and repeated quit attempts, resulting in an intervention called ART+ to improve outcomes over time.
The innovative use of web-based platform technology in the current proposal will remove numerous barriers that often prevent smokers experiencing homelessness from accessing high-quality, evidence-based care.
There is tremendous inequity in smoking-related outcomes for VEH.
The innovative use of mobile health technology in the current proposal will remove numerous barriers that often prevent Veterans who smoke and experience homelessness from accessing high- quality, evidence-based care.
Specific Aims: Aim 1: Evaluate the comparative effectiveness of ART+ on bio-verified abstinence outcomes at three-, six-and 12-month follow-ups.
The primary endpoint will be bioverified prolonged abstinence at the six-month follow-up.
Aim 2: Assess the relative cost-effectiveness of ART+ to VA standard care smoking cessation on quality adjusted life years (QALY).
Aim 3: Qualitatively evaluate implementation determinants of ART+ within Specialty Smoking Clinics and VA primary care for VEH programs.
Methodology: 120 Veterans experiencing homelessness who smoke cigarettes will be randomly assigned to ART+ or to VA standard smoking cessation care.
Self-reported and bioverified abstinence at six months are the primary outcomes.
Cost-effectiveness analyses will be performed using QALY as the effectiveness measure.
Rapid qualitative analytic methods will be used to evaluate implementation determinants of ART+ following enrollment of all study participants.
Participants for the qualitative analysis will include clinicians and clinical support staff who provide care to Veterans experiencing homelessness, designated VA operations partners, and VA Tobacco Treatment Specialists.
Purposive sampling will be used to identify potential participants and a structured interview guide based upon domains from the Consolidated Framework for Implementation Research (CFIR) will be administered.
The investigators will use rapid qualitative analysis to answer the key qualitative research question: "What determinants will impact implementation of ART+?"
The benefit of decreasing tobacco use (Aim 1) among VEH who smoke is tremendous as it will prevent significant morbidity and mortality.
Moreover, if ART+ is shown to be cost effective (Aim 2) and implementation determinants are identified (Aim 3), the use of mobile phones as a platform to provide behavioral incentives has the potential to transform the delivery of smoking cessation care.
Path to Translation/Implementation: Cost-effectiveness analysis (Aim 2) will help guide implementation decisions.
Qualitative evaluation of the implementation determinants of ART+ within Specialty Smoking Clinics and VA primary care for VEH programs (Aim 3) will provide important information on effective implementation of ART+.
Tipo de estudio
Intervencionista
Inscripción (Estimado)
120
Fase
- No aplica
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Estudio Contacto
- Nombre: Angela C Kirby, MS
- Número de teléfono: 7456 (919) 286-0411
- Correo electrónico: angela.kirby@va.gov
Ubicaciones de estudio
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27705-3875
- Durham VA Medical Center, Durham, NC
-
Contacto:
- Angela C Kirby, MS
- Número de teléfono: 7456 919-286-0411
- Correo electrónico: angela.kirby@va.gov
-
Investigador principal:
- Jean C Beckham, PhD
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
No
Descripción
Inclusion Criteria:
- Are homeless
- Smoke at least 5 cigarettes daily with CO indicating current smoking at time of screening assessment
- Are willing to try to quit smoking in next 30 days
Exclusion Criteria:
- Have uncontrolled psychotic symptoms
- Have active substance dependence other than nicotine (participants in partial remission with at least one month sobriety will be included)
- Have severely impaired hearing or speech
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Abstinence Reinforcement Therapy +
Abstinence Reinforcement Therapy +, or ART+, includes five sessions and several booster sessions of cognitive-behavioral therapy for smoking cessation, two forms of nicotine replacement therapy plus bupropion or varenicline, and mobile contingency management for smoking cessation.
|
Five core sessions of CBT plus up to four monthly booster sessions designed to help Veterans prepare to quit smoking, make a quit attempt, and prevent relapse to smoking.
Otros nombres:
NRT is a group of over-the-counter medications designed to help users quit smoking.
Standard of care often involves use of nicotine patch plus one rescue method (either gum or lozenge).
Otros nombres:
Bupropion is an FDA-approved prescription smoking cessation aid.
Participants will be prescribed 150-300 mg.
Otros nombres:
Varenicline is an FDA-approved prescription smoking cessation aid.
Participants will be 0.5 to 2 mg.
Otros nombres:
Smoking abstinence will be intermittently reinforced.
For each carbon monoxide (CO) reading that a participant provides that suggest smoking abstinence, the participant will earn spins on a virtual prize wheel that has financial prizes.
Otros nombres:
|
|
Comparador activo: Standard Care Condition
Standard Care Condition will involve referral to local VA clinic-based smoking cessation care.
This care often includes pharmacotherapy, counseling options, and/or use of a telephone-based, texting-based or app-based smoking cessation program.
|
NRT is a group of over-the-counter medications designed to help users quit smoking.
Standard of care often involves use of nicotine patch plus one rescue method (either gum or lozenge).
Otros nombres:
Bupropion is an FDA-approved prescription smoking cessation aid.
Participants will be prescribed 150-300 mg.
Otros nombres:
Varenicline is an FDA-approved prescription smoking cessation aid.
Participants will be 0.5 to 2 mg.
Otros nombres:
Participants assigned to the usual care condition may participate in group counseling for smoking cessation, which can also include use of phone-based smoking cessation resources such as a telephone quit line, a texting program, and a smoking cessation app.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants whose self-report of prolonged smoking abstinence is bioverified
Periodo de tiempo: 6-month follow-up, about six months after baseline
|
Prolonged abstinence is defined as 30 days abstinent.
For participants who are not using NRT/vapes/e-cigarettes at follow-up, abstinence will be based upon: 1) self-reported abstinence; 2) no biochemical samples indicating smoking (CO ≥ 5 ppm or cotinine ≥ 6 ng/mL); and 3) at least one sample indicating abstinence (CO < 5 ppm and/or cotinine < 6 ng/mL)
|
6-month follow-up, about six months after baseline
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of participants whose self-report of prolonged smoking abstinence is bioverified
Periodo de tiempo: 3-month follow-up, about three months after baseline
|
Prolonged abstinence is defined as 30 days abstinent.
For participants who are not using NRT/vapes/e-cigarettes at follow-up, abstinence will be based upon: 1) self-reported abstinence; 2) no biochemical samples indicating smoking (CO ≥ 5 ppm or cotinine ≥ 6 ng/mL); and 3) at least one sample indicating abstinence (CO < 5 ppm and/or cotinine < 6 ng/mL)
|
3-month follow-up, about three months after baseline
|
|
Number of participants whose self-report of prolonged smoking abstinence is bioverified
Periodo de tiempo: 12-month follow-up, about twelve months after baseline
|
Prolonged abstinence is defined as 30 days abstinent.
For participants who are not using NRT/vapes/e-cigarettes at follow-up, abstinence will be based upon: 1) self-reported abstinence; 2) no biochemical samples indicating smoking (CO ≥ 5 ppm or cotinine ≥ 6 ng/mL); and 3) at least one sample indicating abstinence (CO < 5 ppm and/or cotinine < 6 ng/mL
|
12-month follow-up, about twelve months after baseline
|
|
Number of participants who self-report 7-day point prevalence abstinence
Periodo de tiempo: 3-month follow-up, about three months after baseline
|
7-day point prevalence abstinence is defined as no smoking in the prior 7 days
|
3-month follow-up, about three months after baseline
|
|
Number of participants who self-report 7-day point prevalence abstinence
Periodo de tiempo: 6-month follow-up, about six months after baseline
|
7-day point prevalence abstinence is defined as no smoking in the prior 7 days
|
6-month follow-up, about six months after baseline
|
|
Number of participants who self-report 7-day point prevalence abstinence
Periodo de tiempo: 12-month follow-up, about twelve months after baseline
|
7-day point prevalence abstinence is defined as no smoking in the prior 7 days
|
12-month follow-up, about twelve months after baseline
|
|
Number of participants who self-report 30-day point prevalence abstinence
Periodo de tiempo: 3-month follow-up, about three months after baseline
|
7-day point prevalence abstinence is defined as no smoking in the prior 30 days
|
3-month follow-up, about three months after baseline
|
|
Number of participants who self-report 30-day point prevalence abstinence
Periodo de tiempo: 6-month follow-up, about six months after baseline
|
7-day point prevalence abstinence is defined as no smoking in the prior 30 days
|
6-month follow-up, about six months after baseline
|
|
Number of participants who self-report 30-day point prevalence abstinence
Periodo de tiempo: 12-month follow-up, about twelve months after baseline
|
30-day point prevalence abstinence is defined as no smoking in the prior 30 days
|
12-month follow-up, about twelve months after baseline
|
|
Number of participants who self-report early continuous abstinence
Periodo de tiempo: 3-month follow-up, about three months after baseline
|
Early continuous abstinence will be defined as reporting two weeks of continuous abstinence during the first four weeks after the quit day
|
3-month follow-up, about three months after baseline
|
|
Incremental Cost-Effectiveness Ratio
Periodo de tiempo: 12 months post quit, about 12 months after baseline
|
Measure of cost-effectiveness; costs as the numerator and effectiveness as measured by quality-adjusted life years (QALY) as the denominator.
|
12 months post quit, about 12 months after baseline
|
|
Percentage of carbon monoxide reading completion by participants in ART+ intervention group
Periodo de tiempo: 3-month follow-up, about three months after baseline
|
Patient intervention utilization will be measured by the percentage of prompted carbon monoxide readings that participants in the ART+ condition complete during the treatment period.
|
3-month follow-up, about three months after baseline
|
|
Number of behavioral cognitive-behavioral therapy (CBT) sessions completed by participants in ART+ intervention group
Periodo de tiempo: 3-month follow-up, about three months after baseline
|
Patient intervention utilization will be measured by the number of behavioral cognitive-behavioral therapy (CBT) sessions completed by participants in the ART+ condition during the treatment period
|
3-month follow-up, about three months after baseline
|
|
Number of participants in ART+ intervention group who withdraw or are lost to contact during the treatment period
Periodo de tiempo: 3-month follow-up, about three months after baseline
|
Patient intervention utilization will be measured by the number of participants in ART+ intervention group who withdraw or are lost to contact during the treatment period.
|
3-month follow-up, about three months after baseline
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Patrocinador
Investigadores
- Investigador principal: Jean C Beckham, PhD, Durham VA Medical Center, Durham, NC
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio (Estimado)
1 de marzo de 2027
Finalización primaria (Estimado)
1 de marzo de 2030
Finalización del estudio (Estimado)
1 de septiembre de 2030
Fechas de registro del estudio
Enviado por primera vez
15 de julio de 2026
Primero enviado que cumplió con los criterios de control de calidad
15 de julio de 2026
Publicado por primera vez (Actual)
20 de julio de 2026
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
20 de julio de 2026
Última actualización enviada que cumplió con los criterios de control de calidad
15 de julio de 2026
Última verificación
1 de julio de 2026
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Desordenes mentales
- Trastornos relacionados con sustancias
- Trastornos inducidos químicamente
- Comportamiento
- Trastorno por consumo de tabaco
- De fumar
- Químicos orgánicos
- Piridina
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Terapéutica
- Terapia con drogas
- Alimento
- Dieta, alimentos y nutrición
- Fenómeno fisiológico
- Comida y bebidas
- Carbohidratos
- Alcaloides
- Terapia conductual
- Psicoterapia
- Disciplinas y actividades de comportamiento
- Polímeros
- Sustancias macromoleculares
- Polisacáridos
- Benzazepines
- Cetonas
- Biopolímeros
- Quinoxalinas
- Encías vegetales
- Dulce
- Alcaloides solanáceos
- Goma de mascar
- Propiofenones
- Vareniclina
- Nicotina
- Bupropión
- Terapia cognitiva conductual
- Tobacco Use dispositivos de cesación
- Terapia de reemplazo de nicotina
- Chicle de nicotina
Otros números de identificación del estudio
- HSR2-003-25M
- 1924743 (Otro identificador: Durham VA Medical Center IRB)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
NO
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
No
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
No
producto fabricado y exportado desde los EE. UU.
No
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .